Casdin Partners
Backing AI companies from USA
$2.4B
Awaira Score
out of 100
Casdin Partners focuses on AI, Genomics, Health. They typically invest at the Growth stage. With $2.4B under management, they've got the firepower to write big checks. They've backed 2 AI companies so far.
Investment Strategy Analysis
Casdin Partners operates a thesis-driven portfolio concentrated in AI, Genomics, Health, with a geographic base in USA. By concentrating on Growth deals, the firm has developed pattern recognition and network advantages at that particular stage of the funding lifecycle. Managing $2.4B across 2 known investments suggests a concentrated, high-conviction approach to AI investing. The firm holds a solid position among tracked AI investors, with room to grow its footprint in the ecosystem.
Score
68/100
AUM
$2.4B
Portfolio Size
2
Founded
2011
Stage Focus
Growth
Country
🇺🇸 USA
Assets Under Mgmt
$2.4B
Total capital managed
Portfolio Companies
2
Companies backed
Stage Focus
Growth
Preferred investment stage
Estimated Portfolio Value
Sum of all tracked company valuations
$2.2B
Focus Areas
About Casdin Partners
Casdin Partners is a growth-stage investment firm founded in 2011, headquartered in USA, managing approximately $2.4B in assets under management. The firm concentrates on AI, Genomics, Health, deploying capital primarily at the growth level. Notable AI portfolio companies include 23andMe, Illumina. Casdin Partners has participated in 2 funding rounds tracked by Awaira, deploying capital across AI, Genomics, Health sectors. The firm's investment strategy emphasizes AI applications in healthcare and life sciences. Awaira assigns Casdin Partners an investor score of 68/100 based on portfolio strength, AI sector exposure, and market activity. The firm investment thesis centers on identifying AI companies that demonstrate strong technical moats, clear paths to revenue, and potential for category leadership within their respective segments. Casdin Partners evaluates opportunities based on team quality, market timing, technology differentiation, and capital efficiency. Portfolio companies including 23andMe, Illumina reflect the firm emphasis on backing founders who combine deep technical expertise with commercial execution capability.
Founded: 2011
Investment Focus
Portfolio Companies(1)
Portfolio Metrics
Companies
1
Categories
1
Top Sector
AI Healthcare (1)
Avg Score
73/100
Frequently Co-Invests With
Notable Deal
Casdin Partners is a growth-stage investment firm founded in 2011, headquartered in USA, managing approximately $2.4B in assets under management. The firm concentrates on AI, Genomics, Health, deploying capital primarily at the growth level. Notable AI portfolio companies include 23andMe, Illumina. Casdin Partners has participated in 2 funding rounds tracked by Awaira, deploying capital across AI, Genomics, Health sectors. The firm's investment strategy emphasizes AI applications in healthcare and life sciences. Awaira assigns Casdin Partners an investor score of 68/100 based on portfolio strength, AI sector exposure, and market activity. The firm investment thesis centers on identifying AI companies that demonstrate strong technical moats, clear paths to revenue, and potential for category leadership within their respective segments. Casdin Partners evaluates opportunities based on team quality, market timing, technology differentiation, and capital efficiency. Portfolio companies including 23andMe, Illumina reflect the firm emphasis on backing founders who combine deep technical expertise with commercial execution capability.
Investment Track Record
AUM
$2.4B
Notable Deal
Casdin Partners is a growth-stage investment firm ...
Founded
2011
Stage
Growth
Casdin Partners manages $2.4B, deploying capital with conviction into AI opportunities that match their thesis.
Portfolio News
Explore More